Immune-modulatory effects of Spindlin-1 inhibitors

Area of Science:

• Immunology
• Cancer Biology
• Epigenetics

Background:

• Spindlin-1 is a novel epigenetic reader and a potential cancer therapy target.
• Modulating histone mark recognition by Spindlin-1 may influence the immune system's anticancer capabilities.
• Understanding Spindlin-1 inhibitor effects on immune cells is crucial for therapeutic development.

Purpose of the Study:

• To investigate the impact of Spindlin-1 inhibition on various immune cell types.
• To differentiate between drug-specific and target-specific effects of Spindlin-1 inhibitors A366 and MS31.
• To assess the potential immunomodulatory consequences of Spindlin-1 targeted cancer therapy.

Main Methods:

• Cytotoxicity assays were performed on different immune cell types to determine IC50 values.
• Macrophage polarization (M1/M2) was analyzed by measuring cytokine and surface marker expression.
• T cell activation and B cell proliferation, differentiation, and immunoglobulin production were assessed following inhibitor treatment.

Main Results:

• Spindlin-1 inhibitors A366 and MS31 exhibited dose-dependent cytotoxicity across immune cells, with macrophages being less susceptible than lymphocytes.
• MS31 induced M1 to M2 macrophage polarization, while both inhibitors impaired M2 polarization.
• Both inhibitors significantly suppressed B cell activation, proliferation, and immunoglobulin production at low concentrations, with A366 increasing B cell metabolism.

Conclusions:

• Spindlin-1 inhibition has minimal impact on macrophage polarization and T cell activation but profoundly inhibits B cell activation.
• Spindlin-1 inhibitors may possess dual action: anticancer effects alongside suppression of the humoral immune response.
• Therapeutic targeting of Spindlin-1 could increase susceptibility to infections due to impaired humoral immunity.